A. J. Giaccia

The colocatome as a spatial -omic reveals shared microenvironment features between tumour-stroma assembloids and lung cancer specimens

The paper introduces the colocatome, a spatial-omic framework, to compare microenvironment features between tumour-stroma assembloids and lung cancer specimens, finding that fibroblasts protect cancer cells from treatment by reorganizing cytoarchitecture.

Innate immune receptor C5aR1 regulates cancer cell fate and can be targeted to improve radiotherapy in tumours with immunosuppressive microenvironments

This study identifies C5aR1 as a targetable receptor on cancer cells that enhances radiotherapy efficacy in immunosuppressive tumours by promoting apoptosis without affecting normal tissues.

Hypoxia-mediated regulation of DDX5 through decreased chromatin accessibility and post-translational targeting restricts R-loop accumulation

The paper shows hypoxia reduces DDX5 expression by decreasing chromatin accessibility and post-translational targeting, which limits R-loop accumulation in cancer cells.

Multi-Omics Analysis of Fibroblasts from the Invasive Tumor Edge Reveals that Tumor-Stroma Crosstalk Induces O-glycosylation of the CDK4-pRB Axis

The paper analyzes multi-omics data from fibroblasts at the tumor edge and core to show O-glycosylation of the CDK4-pRB axis is induced by tumor-stroma crosstalk.

Developing High-Affinity Decoy Receptor Optimized for Multiple Myeloma and Diffuse Large B Cell Lymphoma Treatment

This paper develops an engineered sBCMA-Fc fusion protein with enhanced binding affinity to APRIL and BAFF, showing improved antitumor activity against multiple myeloma and diffuse large B cell lymphoma in preclinical models.

Targeting C5aR1 Increases the Therapeutic Window of Radiotherapy

This study shows that targeting C5aR1 with PMX205 improves tumor radiation response and reduces normal tissue toxicity in mice.

Neutralizing PD-L1 and PD-L2 Enhances the Efficacy of Immune Checkpoint Inhibitors in Ovarian Cancer.

The paper develops a high-affinity sPD-1 decoy molecule that neutralizes both PD-L1 and PD-L2, showing superior antitumor activity in ovarian cancer models compared to PD-1/PD-L1 antibodies.